Status:
COMPLETED
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Lung cancer
- Only one prior regimen of chemotherapy for the treatment of non small cell lung cancer
- Adequate bone marrow function
- Adequate liver function
- Adequate renal function
- Negative serum pregnancy test
- Exclusion criteria:
- History of another primary malignancy in the last 5 years
- Having recently received an investigational drug
- Having recently received major surgery of wide field radiotherapy
- Chronic treatment with immunosuppressive therapy, steroids or liver enzyme modulators
- Severe or uncontrolled medical conditions
- Other protocol-defined inclusion/exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00434174
Start Date
December 1 2006
End Date
December 1 2010
Last Update
December 21 2020
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Camperdown, New South Wales, Australia, 2050
2
Novartis Investigative Site
Melbourne, Victoria, Australia, 3002
3
Novartis Investigative Site
Leuven, Belgium, 3000
4
Novartis Investigative Site
Cologne, Germany, 50924